Case ID:

This invention describes a set of novel molecules that target and degrade DYRK/CLK for several potential therapeutic purposes.

Proteolysis-targeting chimeric molecules (PROTACs) are small molecules used to decrease a gene’s protein expression by targeting the protein for ubiquitination and degradation after it is created. This mechanism has applications in a range of therapeutics. One class of targets with therapeutic potential is the DYRK/CLK class of proteins. DYRK/CLK is associated with severity of COVID-19 infections, glioblastoma, and cognitive impairment such as Alzheimer’s Disease.

In this technology, the inventors purpose a novel set of PROTACS molecules that target DYRK/CLK for ubiquitination and degradation for a range of potential therapeutic applications. The ligand that is tethered through a variety of linkers to an E3-ligase recruiter is novel relative to other PROTACs.


  • Therapeutic potential against:
    • Severe COVID-19 infection
    • Cognitive disorders such as Alzheimer’s Disease
    • Glioblastoma


  • Novel PROTAC
  • High specificity
  • Broad range of applications
Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Christopher Hulme
Kevin Schofield
Walter Becker
Garrit Wilms